Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTHGet Free Report) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Roth Mkm reiterated a “buy” rating and set a $20.00 target price on shares of Bio-Path in a research report on Monday, July 8th.

View Our Latest Analysis on Bio-Path

Bio-Path Stock Down 7.5 %

NASDAQ:BPTH opened at $0.98 on Thursday. Bio-Path has a fifty-two week low of $0.85 and a fifty-two week high of $13.90. The firm’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.76.

Bio-Path (NASDAQ:BPTHGet Free Report) last issued its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same quarter in the previous year, the firm earned ($10.60) earnings per share. As a group, analysts forecast that Bio-Path will post -6.2 EPS for the current year.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTHFree Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is owned by hedge funds and other institutional investors.

Bio-Path Company Profile

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

See Also

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.